




The relative strengths and weaknesses of Revance Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 9.5% points. The greatest weakness of Revance Therapeutics Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 126%, being 87% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	338,865
Cost of Goods Sold	0
Intangible Assets	9,808
Liabilities, Current	89,224
Liabilities, Non-Current	540,834
Other Assets	112,556
Other Compr. Net Income	388
Other Expenses	193,331
Other Liabilities	0
Other Net Income	12,447
Other Revenues	234,040
Property and Equipment	17,225
Research and Development	79,410
Selling, General and Administrative Expense	297,732

Output Variable	Value in 1000 USD
Assets	478,454
Liabilities	630,058
Expenses	570,473
Revenues	234,040
Stockholders Equity	-151,604
Net Income	-323,986
Comprehensive Net Income	-323,792
BaseVar	962,930
ECR before LimitedLiability	-118%
Economic Capital Ratio	126%